[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gene-abnormality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gene-abnormality":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,67,99,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100512997","adult-acute-lymphoblastic-leukemia-treated-with-pediatric-regimen-in-brazil-100512997",false,"NCT05959720","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study","BRALLA","Inclusion Criteria: Patients between 16 and 50 years-old with newly diagnosed ALL, negative for Philadelphia chromosome not previously treated (except for hydroxyurea, corticosteroids, or intrathecal chemotherapy) with 20% or more lymphoblasts in bone marrow or peripheral blood.\n\nExclusion Criteria:\n\n* Burkitt leukemia\n* Prior myeloproliferative disease\n* Philadelphia chromosome positivity through whichever methodology (RT-PCR, FISH, or conventional karyotype)\n* ECOG\\>2 (appendix 3)\n* Total bilirubin\\>2x upper limit of normal (ULN)\n* Transaminases\\>5x ULN\n* Creatinine\\>2,5 mg\u002Fdl\n* Positive serology for HIV or HTLV\n* Heart failure NYHA Class III or IV (appendix 4)\n* Severe psychiatric disorder which prevents adequate compliance\n* Prior treatment with intravenous chemotherapy\n* Refusal to participate in the study\n* Down syndrome","ALL","16 Years","50 Years",{"count":21,"type":22},180,"ESTIMATED","2 Years","OBSERVATIONAL","In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic\u002Ffollow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.",[27,28,29,30],"Acute Lymphoid Leukemia","Minimal Residual Disease","Gene Abnormality","Chemotherapeutic Toxicity","RECRUITING","2025-05-03",{"date":34,"type":35},"2025-05-07","ACTUAL",{"date":37,"type":35},"2023-09-05",{"date":39,"type":22},"2030-06",{"name":41,"class":42},"Instituto do Cancer do Estado de São Paulo","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":48,"conditions":52,"keywords":54,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100382769","correlation-between-driver-gene-abnormalities-and-clinicopathological-characteristics-and-disease-prognosis-in-lymphoma-100382769","NCT04263935","Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma","Inclusion Criteria:\n\n1. Diagnosed as lymphoma (according to WHO 2017 classification criteria)\n2. Life expectancy no less than 3 months\n3. Agreeing to sign the written informed consents\n\nExclusion Criteria:\n\n1. Other malignant tumor history or active malignant tumor need be treated\n2. Researchers determine unsuited to participate in this trial",{"count":51,"type":22},200,[53,29],"Lymphoma",[53,55,56],"Driver Gene Abnormalities","Disease Prognosis","2025-04-18",{"date":59,"type":35},"2025-04-23",{"date":61,"type":35},"2019-01-03",{"date":63,"type":22},"2025-12-31",{"name":65,"class":66},"Henan Cancer Hospital","OTHER_GOV",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100580788","phase-1-spermatogonial-differentiation-via-testicular-organoid-100580788","NCT06841861","Spermatogonial Differentiation Via Testicular Organoid","A Study of Therapeutic Spermatogonial Differentiation for Infertile Men Via Testicular Organoid","SDTO","Inclusion Criteria: Group 1 (Fertile Control)\n\n* Male sex of reproductive age (between 18 - 60 years old).\n* Evidence of fertility or normal spermatogenesis.\n* Will undergo study procedures in conjunction with their planned fertility or infertility procedures performed for clinical purposes.\n\nInclusion Criteria: Group 2 and 3 (Infertile)\n\n* Male sex of reproductive age (between 18 - 60 years old).\n* Males with evidence of \\>1 year of infertility.\n* Posesses diagnosis of azoospermia is on clinical evaluation.\n* Will undergo study procedures in conjunction with their planned fertility or infertility procedures performed for clinical purposes.\n\nExclusion Criteria:\n\n\\- The lack of diagnosis of fertility or infertility, and lack of testicles.",true,"MALE","18 Years","60 Years",{"count":80,"type":22},100,"INTERVENTIONAL",[83,84],"PHASE1","PHASE2","Purpose:\n\nThis clinical trial aims to explore the potential for human sperm production in vitro by sustaining a laboratory-cultured adult testicular environment. It also seeks to identify genetic factors contributing to human sterility and failed spermatogenesis. The study's primary objectives include:\n\n1. Identifying genomic markers associated with sterility and failed spermatogenesis.\n2. Developing an ex vivo (outside the body) testis \"organ-on-a-chip\" (\"iTestis\") to support stem cell cultivation.\n3. Determining whether human spermatogenesis can be re-created in vitro using stem cells nurtured in the iTestis model.\n\nStudy Description:\n\nResearchers will analyze the genomic profiles of fertile and sterile male participants to map genetic abnormalities associated with sterility. Using testicular and skin tissue samples from participants, spermatogonial stem cells and pluripotent stem cells will be isolated and utilized to construct the ex vivo iTestis. This system will integrate genomic insights and prior research to foster human spermatogenesis outside the body.\n\nParticipant Involvement:\n\nParticipants will provide the following samples:\n\n* Blood sample for serum analysis.\n* A skin tissue biopsy.\n* Testicular tissue, obtained through fine needle aspiration (FNA) or testicular sperm extraction (TESE), as part of a routine procedure.\n\nAll procedures will be conducted by the principal investigator and qualified research staff, ensuring participant safety and adherence to ethical guidelines.",[87,29,88],"Infertility, Male","Sterility, Male","2025-02-20",{"date":91,"type":35},"2025-02-24",{"date":93,"type":35},"2024-03-28",{"date":95,"type":22},"2027-01-01",{"name":97,"class":98},"CellARTs Inc.","INDUSTRY",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":105,"enrollmentInfo":106,"targetDuration":108,"studyType":24,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100537484","genotype-phenotype-and-disease-progression-of-developmental-epileptic-encephalopathy-with-onset-before-2-years-of-age-100537484","NCT06278428","Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age","Inclusion Criteria:\n\n1. Diagnosed with Early infantile developmental and epileptic encephalopathy or Epilepsy of infancy with migrating focal seizures or infantile spasms syndrome or severe myoclonic epilepsy of infancy or Epilepsy with myoclonic-atonic seizures\n2. Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria\n3. Age at the start of participating in the study ranged from 0 to 23 months old\n4. Relatives agree to participate in the research\n5. There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage.\n\nExclusion Criteria:\n\nPatients were removed from the study when they were lost to follow-up at 6 months\n\n\\-","23 Months",{"count":107,"type":22},50,"24 Months","According to estimates by the World Health Organization in 2019, more than 50 million people around the world have epilepsy. Nearly 80% of patients with epilepsy live in developing countries. Among them, children under 2 years old are the group with the highest incidence of epilepsy, and at the same time, the most dangerous epilepsy groups are also likely to start at these ages. World medical literature on epileptic encephalopathy and early-onset development before 2 years of age records that 71% of children have severe intellectual disability and 60% of children show signs of autism spectrum disorder, of which Children with epileptic and developmental encephalopathy due to genetic causes are at higher risk of developing neurodevelopmental disorders than children with epileptic and developmental encephalopathy due to other causes. However, in Vietnam, there is no research on this topic.\n\nThe question is what are the phenotypes, genotypes, and progression after 2 years of follow-up of Vietnamese children with epileptic and developmental encephalopathy with onset before 2 years of age?",[111,112,29,113],"Epilepsy; Seizure","Child Development","Early Onset Disorder","2025-01-08",{"date":116,"type":35},"2025-01-09",{"date":118,"type":35},"2024-02-27",{"date":120,"type":22},"2028-11-01",{"name":122,"class":42},"Number 2 Children's Hospital, Ho Chi Minh City",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":43},"100300548","icages-guided-precision-therapy-for-cancers-in-contrast-to-standard-care-or-ihc-guided-theray-100300548","NCT03192501","iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray","Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers","Inclusion Criteria:\n\n* Pathological and clinical diagnosis of recurrence \u002F metastatic lung cancer or other advanced cancers.\n* There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.\n* The patient is informed consent and signed a written consent.\n\nExclusion Criteria:\n\n* Age \\> 70 or \\\u003C18 years old.\n* Previous history of malignant tumors.\n* Pregnant or lactating female patients.\n* Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.","70 Years",{"count":133,"type":22},250,"This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.",[136,29,137,138],"Lung Cancer","Gene Product Sequence Variation","Cancer",[140,141,142,143,144,145,146],"lung cancer","iCAGES","gene mutation","precision medicine","advanced cancers","IHC","Targeted therapy","2024-06-22",{"date":149,"type":35},"2024-06-25",{"date":151,"type":35},"2017-07-01",{"date":153,"type":22},"2039-07-01",{"name":155,"class":42},"Second Affiliated Hospital of Guangzhou Medical University"]